Lung Cancer Trial, Recruiting NCT04937283 Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT04937283
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 20 and 79 years old, male or female
  • People whose tumor measures 2cm or smaller on a CT scan taken before surgery
  • People with a single nodule located in the outer part of the lung, or where the associated growth is a minimally invasive or less invasive type
  • People whose pre-surgery CT scan shows the nodule is not a "pure ground glass" type — meaning it has a solid component making up at least 25% of the nodule
  • People whose tissue sample taken during surgery (frozen section) confirms invasive lung adenocarcinoma, with less than or equal to 5% of certain aggressive subtypes (micropapillary and solid)
  • People whose tissue sample taken during surgery confirms no tumor cells are present at the surgical edges
  • People whose lung function is strong enough to support either a segmentectomy or a lobectomy (a breathing test result above certain thresholds — confirm with trial site)
  • People with a general physical fitness score of 0 to 2 on a standard scale used in oncology (meaning able to carry out normal daily activities, with at most moderate limitations)
  • People who are willing to participate, can sign a consent form, and are able to attend follow-up appointments as required

Who may not be able to join:

  • People whose CT scan shows a nodule that is entirely "pure ground glass" with less than 25% solid component
  • People whose nodule is located too close to the central part of the lung to allow a segmentectomy to be performed
  • People whose tissue sample taken during surgery shows more than 5% of the aggressive subtypes (micropapillary and solid)
  • People whose tissue sample taken during surgery shows a very early-stage, non-invasive type of adenocarcinoma
  • People whose pre-surgery imaging or airway ultrasound (EBUS) shows cancer has spread to the lymph nodes
  • People whose pre-surgery imaging shows cancer has spread to distant parts of the body
  • People with severely reduced heart, liver, or kidney function at certain levels (confirm specific thresholds with trial site)
  • People who have another type of cancer
  • People who are pregnant, planning to become pregnant, or currently breastfeeding
  • People who have previously received chemotherapy, radiation therapy, or other cancer treatments
  • People who have taken part in another tumor-related clinical trial within the past three months
  • People who the trial investigators assess as unsuitable for participation for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chang Chen, MD, PhD, Shanghai Pulmonary Hospital, School of Medicine, Tongji University

Phone: +86 13917810850

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Registry
ClinicalTrials.gov
Start date
1 October 2019
Est. completion
30 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

recurrence-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov